FZD7, widely known as the most common reporter of Wnt, has been recognized as a target for cancer therapy, as it can play an important role in controlling endothelial cell proliferation by inhibiting the Wnt–β-catenin signaling regulators [35]. This evidence concerns the gene FZD7 and cancer.